Hospital case-volume is associated with case-fatality after aneurysmal subarachnoid hemorrhage.


Journal

International journal of stroke : official journal of the International Stroke Society
ISSN: 1747-4949
Titre abrégé: Int J Stroke
Pays: United States
ID NLM: 101274068

Informations de publication

Date de publication:
04 2019
Historique:
pubmed: 19 7 2018
medline: 22 1 2020
entrez: 19 7 2018
Statut: ppublish

Résumé

Inverse association between hospital case-volume and case-fatality has been observed for various nonsurgical interventions and surgical procedures. To study the impact of hospital case-volume on outcome after aneurysmal subarachnoid hemorrhage (aSAH). We included aSAH patients who underwent aneurysm coiling or clipping from tertiary care medical centers across three continents using the Dr Foster Stroke GOAL database 2007-2014. Hospitals were categorized by annual case-volume (low volume: <41/year; intermediate: 41-70/year; high: >70/year). Primary outcome was 14-day in-hospital case-fatality. We calculated proportions, and used multiple logistic regression to adjust for age, sex, differences in comorbidity or disease severity, aneurysm treatment modality, and hospital. We included 8525 patients (2363 treated in low volume hospitals, 3563 treated in intermediate volume hospitals, and 2599 in high-volume hospitals). Crude 14-day case-fatality for hospitals with low case-volume was 10.4% (95% confidence interval (CI) 9.2-11.7%), for intermediate volume 7.0% (95% CI 6.2-7.9%; adjusted odds ratio (OR) 0.63 (95%CI 0.47-0.85)) and for high volume 5.4% (95% CI 4.6-6.3%; adjusted OR 0.50 (95% CI 0.33-0.74)). In patients with clipped aneurysms, adjusted OR for 14-day case-fatality was 0.46 (95% CI 0.30-0.71) for hospitals with intermediate case-volume and 0.42 (95% CI 0.25-0.72) with high case-volume. In patients with coiled aneurysms, adjusted OR was 0.77 (95% CI 0.55-1.07) for hospitals with intermediate case-volume and 0.56 (95% CI 0.36-0.87) with high case-volume. Even within a subset of large, tertiary care centers, intermediate and high hospital case-volume is associated with lower case-fatality after aSAH regardless of treatment modality, supporting centralization to higher volume centers.

Sections du résumé

BACKGROUND
Inverse association between hospital case-volume and case-fatality has been observed for various nonsurgical interventions and surgical procedures.
AIMS
To study the impact of hospital case-volume on outcome after aneurysmal subarachnoid hemorrhage (aSAH).
METHODS
We included aSAH patients who underwent aneurysm coiling or clipping from tertiary care medical centers across three continents using the Dr Foster Stroke GOAL database 2007-2014. Hospitals were categorized by annual case-volume (low volume: <41/year; intermediate: 41-70/year; high: >70/year). Primary outcome was 14-day in-hospital case-fatality. We calculated proportions, and used multiple logistic regression to adjust for age, sex, differences in comorbidity or disease severity, aneurysm treatment modality, and hospital.
RESULTS
We included 8525 patients (2363 treated in low volume hospitals, 3563 treated in intermediate volume hospitals, and 2599 in high-volume hospitals). Crude 14-day case-fatality for hospitals with low case-volume was 10.4% (95% confidence interval (CI) 9.2-11.7%), for intermediate volume 7.0% (95% CI 6.2-7.9%; adjusted odds ratio (OR) 0.63 (95%CI 0.47-0.85)) and for high volume 5.4% (95% CI 4.6-6.3%; adjusted OR 0.50 (95% CI 0.33-0.74)). In patients with clipped aneurysms, adjusted OR for 14-day case-fatality was 0.46 (95% CI 0.30-0.71) for hospitals with intermediate case-volume and 0.42 (95% CI 0.25-0.72) with high case-volume. In patients with coiled aneurysms, adjusted OR was 0.77 (95% CI 0.55-1.07) for hospitals with intermediate case-volume and 0.56 (95% CI 0.36-0.87) with high case-volume.
CONCLUSIONS
Even within a subset of large, tertiary care centers, intermediate and high hospital case-volume is associated with lower case-fatality after aSAH regardless of treatment modality, supporting centralization to higher volume centers.

Identifiants

pubmed: 30019632
doi: 10.1177/1747493018790073
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

282-289

Subventions

Organisme : NINDS NIH HHS
ID : R01 NS085419
Pays : United States
Organisme : NINDS NIH HHS
ID : U24 NS107230
Pays : United States

Auteurs

Antti Lindgren (A)

1 Department of Neurology and Neurosurgery, University Medical Center Utrecht, Utrecht, The Netherlands.
2 Department of Neurosurgery, NeuroCenter, Kuopio University Hospital, Kuopio, Finland.

Sarah Burt (S)

3 Dr Foster Ltd, London, UK.

Ellie Bragan Turner (E)

3 Dr Foster Ltd, London, UK.

Atte Meretoja (A)

4 Department of Neurology, Helsinki University Hospital, Helsinki, Finland.
5 Department of Medicine at the Royal Melbourne Hospital, University of Melbourne, Parkville, Australia.

Jin-Moo Lee (JM)

6 Department of Neurology, and the Hope Center for Neurological disorders, Washington University School of Medicine, St. Louis, MO, USA.

Thomas M Hemmen (TM)

7 Department of Neurosciences, University of California, San Diego, CA, USA.

Mark Alberts (M)

8 Department of Neurology, Hartford Hospital, Hartford, CT, USA.

Robin Lemmens (R)

9 KU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology, Leuven Institute for Neuroscience and Disease (LIND), Leuven, Belgium.
10 VIB, Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium.
11 Department of Neurology, University Hospitals Leuven, Leuven, Belgium.

Mervyn DI Vergouwen (MD)

1 Department of Neurology and Neurosurgery, University Medical Center Utrecht, Utrecht, The Netherlands.

Gabriel Je Rinkel (GJ)

1 Department of Neurology and Neurosurgery, University Medical Center Utrecht, Utrecht, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH